1 序文
2 範囲と方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次ソース
2.3.2 二次ソース
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主な業界動向
5 世界の免疫チェックポイント阻害剤市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 種類別市場内訳
6.1 CTLA-4 阻害剤
6.1.1 市場動向
6.1.2 市場予測
6.2 PD-1 阻害剤
6.2.1 市場動向
6.2.2 市場予測
6.3 PD-L1阻害剤
6.3.1 市場動向
6.3.2 市場予測
7 流通チャネル別市場規模
7.1 病院薬局
7.1.1 市場動向
7.1.2 市場予測
7.2 薬局
7.2.1 市場動向
7.2.2 市場予測
7.3 オンライン薬局
7.3.1 市場動向
7.3.2 市場予測
8 用途別市場
8.1 肺癌
8.1.1 市場動向
8.1.2 市場予測
8.2 膀胱癌
8.2.1 市場動向
8.2.2 市場予測
8.3 メラノーマ
8.3.1 市場動向
8.3.2 市場予測
8.4 大腸癌
8.4.1 市場動向
8.4.2 市場予測
8.5 ホジキンリンパ腫
8.5.1 市場動向
8.5.2 市場予測
8.6 その他
8.6.1 市場動向
8.6.2 市場予測
9 地域別市場内訳
9.1 北米
9.1.1 米国
9.1.1.1 市場動向
9.1.1.2 市場予測
9.1.2 カナダ
9.1.2.1 市場動向
9.1.2.2 市場予測
9.2 アジア太平洋地域
9.2.1 中国
9.2.1.1 市場動向
9.2.1.2 市場予測
9.2.2 日本
9.2.2.1 市場動向
9.2.2.2 市場予測
9.2.3 インド
9.2.3.1 市場動向
9.2.3.2 市場予測
9.2.4 韓国
9.2.4.1 市場動向
9.2.4.2 市場予測
9.2.5 オーストラリア
9.2.5.1 市場動向
9.2.5.2 市場予測
9.2.6 インドネシア
9.2.6.1 市場動向
9.2.6.2 市場予測
9.2.7 その他
9.2.7.1 市場動向
9.2.7.2 市場予測
9.3 欧州
9.3.1 ドイツ
9.3.1.1 市場動向
9.3.1.2 市場予測
9.3.2 フランス
9.3.2.1 市場動向
9.3.2.2 市場予測
9.3.3 英国
9.3.3.1 市場動向
9.3.3.2 市場予測
9.3.4 イタリア
9.3.4.1 市場動向
9.3.4.2 市場予測
9.3.5 スペイン
9.3.5.1 市場動向
9.3.5.2 市場予測
9.3.6 ロシア
9.3.6.1 市場動向
9.3.6.2 市場予測
9.3.7 その他
9.3.7.1 市場動向
9.3.7.2 市場予測
9.4 ラテンアメリカ
9.4.1 ブラジル
9.4.1.1 市場動向
9.4.1.2 市場予測
9.4.2 メキシコ
9.4.2.1 市場動向
9.4.2.2 市場予測
9.4.3 その他
9.4.3.1 市場動向
9.4.3.2 市場予測
9.5 中東およびアフリカ
9.5.1 市場動向
9.5.2 国別の市場内訳
9.5.3 市場予測
10 推進要因、阻害要因、および機会
10.1 概要
10.2 推進要因
10.3 阻害要因
10.4 機会
11 バリューチェーン分析
12 ポーターのファイブフォース分析
12.1 概要
12.2 買い手の交渉力
12.3 売り手の交渉力
12.4 競争の度合い
12.5 新規参入の脅威
12.6 代替品の脅威
13 価格分析
14 競合状況
14.1 市場構造
14.2 主要企業
14.3 主要企業のプロフィール
AstraZeneca plc
Bristol-Myers Squibb Company
GSK plc
Merck & Co. Inc
Ono Pharmaceutical Co. Ltd
Pfizer Inc
Regeneron Pharmaceuticals Inc
Seagen Inc
Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.
Immune Checkpoint Inhibitors Market Trends:
The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on type, distribution channel, and application.
Type Insights:
CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor
The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.
Distribution Channel Insights:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.
Application Insights:
Lung Cancer
Bladder Cancer
Melanoma
Colorectal Cancer
Hodgkin Lymphoma
Others
The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.
Key Questions Answered in This Report
1. How big is the global immune checkpoint inhibitors market?
2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2025-2033?
3. What are the key factors driving the global immune checkpoint inhibitors market?
4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
8. What are the key regions in the global immune checkpoint inhibitors market?
9. Who are the key players/companies in the global immune checkpoint inhibitors market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Immune Checkpoint Inhibitors Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 CTLA-4 Inhibitor
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 PD-1 Inhibitor
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 PD-L1 Inhibitor
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Lung Cancer
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Bladder Cancer
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Melanoma
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Colorectal Cancer
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Hodgkin Lymphoma
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AstraZeneca plc
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bristol-Myers Squibb Company
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 GSK plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Merck & Co. Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Ono Pharmaceutical Co. Ltd.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Pfizer Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Regeneron Pharmaceuticals Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Seagen Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
*** 免疫チェックポイント阻害剤の世界市場に関するよくある質問(FAQ) ***
・免疫チェックポイント阻害剤の世界市場規模は？
→IMARC社は2024年の免疫チェックポイント阻害剤の世界市場規模を495億米ドルと推定しています。
・免疫チェックポイント阻害剤の世界市場予測は？
→IMARC社は2033年の免疫チェックポイント阻害剤の世界市場規模を1686億米ドルと予測しています。
・免疫チェックポイント阻害剤市場の成長率は？
→IMARC社は免疫チェックポイント阻害剤の世界市場が2025年～2033年に年平均14.6%成長すると展望しています。
・世界の免疫チェックポイント阻害剤市場における主要プレイヤーは？
→「AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc.など ...」を免疫チェックポイント阻害剤市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
